Purpose Specialty medications can have life-altering outcomes for patients with complex
diseases. However, their benefit relies on appropriate treatment selection, patients' ability to …

Utilization of hepatitis C virus-positive donors in kidney t... : Current Opinion in Organ
Transplantation Utilization of hepatitis C virus-positive donors in kidney transplantation : Current …

Background: Copay cards are intended to mitigate patient out-of-pocket (OOP) expenses.
This qualitative, exploratory focus group study aimed to capture patient perceptions of copay …

Since its identification, HCV has been considered one of the main causes of hepatitis and
liver cancer. Currently, the molecular mechanisms of HCC development induced by HCV …

Direct-acting antiviral agents have facilitated the utilization of hepatitis C virus (HCV)+
organs in HCV nucleic acid amplification test (NAT)–recipients. We evaluated trends in HCV …

Liver diseases after kidney transplantation range from mild biochemical abnormalities to
severe hepatitis or cirrhosis. The causes are diverse and mainly associated with …

Objective The feasibility and 6-month outcome safety of lung transplants (LTs) from hepatitis
C virus (HCV)-viremic donors for HCV-seronegative recipients (R–) were established in …

We evaluate the introduction of direct-acting antiviral (DAA) therapy for Hepatitis C (HCV) on
liver transplant allocation in the United States. We develop a model of listing and organ …

There are limited data regarding heart transplantation in the setting of hepatitis C virus
(HCV) infection in either recipients or donors, as the practice was infrequent, given concerns …

Introduction Utilization of hepatitis C viremic (HCV+) deceased donor kidneys (DDKT) for
aviremic recipients increases opportunities for transplantation with excellent short‐term …